blocks the late component of the Na + current, late I Na (I NaL , a depolarizing current), ranolazine also interacts with and reduces the repolarizing human ether-a-go-go-related gene (hERG) current I Kr with therapeutic concentrations. 10 The result is a mild concentration-dependent QTc prolongation. 11 Ranolazine is thus contraindicated for patients using other QT-prolonging drugs, those with preexisting QT prolongation, 12 or ostensibly those with any form of decreased repolarization reserve. However, patients with QT prolongation from increased I NaL from either inherited defects or disease-induced electric remodeling might be exactly the ones to benefit most from selective targeting of I NaL .
The wealth of genetic information in recent years has led to an increased understanding of how genotype underlies clinical phenotype. For example, the long-QT syndrome type 3 (LQT3), a subset of the congenital long-QT syndrome, is a group of inherited Na + channel mutations that are characterized by a delay in cardiac cellular repolarization, manifesting as a prolongation of the QT interval on the ECG, resultant cardiac arrhythmias, and sudden death. 13 LQT3 mutations manifest clinically similarly (a prolongation on the ECG) but are heterogeneous in mechanisms. Thus, it is not surprising that they also exhibit varied responses to antiarrhythmic drugs. [14] [15] [16] [17] Acquired arrhythmia syndromes such as ischemic heart failure present their own specific challenge, namely the vast heterogeneity of disease phenotypes and the continuum of severity existing throughout the natural course of disease. As opposed to genetically linked ion channel mutations, which have a fairly defined mechanistic basis, the emergent effects of heart failureassociated arrhythmias are the result of multiple intersecting, deranged, and physiological compensatory processes. 18 Another confounding factor in accurate interpretation of antiarrhythmic drug effects results from drug metabolism. For example, ranolazine is extensively biotransformed into active metabolites that exhibit strikingly different affinities to cardiac ion channels than the parent compound. 19, 20 Thus, ex vivo channel expression and cell studies performed outside the physiological milieu where drug metabolism is absent must be interpreted with caution.
In a recent study, 21 we developed a computational modeling approach, informed and validated by experimental data, that simulated the interaction kinetics of the antiarrhythmic drugs flecainide and lidocaine with cardiac Na + channels. We then used the model to predict the drug effects on human ventricular cellular and tissue electric activity and, in the setting of 1 common arrhythmia trigger, spontaneous ventricular ectopy. The model predicted when clinically relevant concentrations of the antiarrhythmic drugs, flecainide and lidocaine, would exacerbate, rather than ameliorate, arrhythmia. Here, we expand this computational framework to predict the effects of promising genotype-specific therapeutic candidates for inherited LQT3-linked arrhythmias as well as acquired arrhythmia syndromes (eg, heart failure) on emergent electric activity in virtual cells and tissue. Computational analyses of diseasespecific alterations and pharmacology present an opportunity to screen drugs for improved phenotype for a given disease process and when a drug should be excluded if it exacerbates arrhythmogenic potential.
Methods
Detailed methods are available in the Online Data Supplement. Source code is available on request.
Results
To compare the potential usefulness of ranolazine as an antiarrhythmic in the setting of LQT3, we expanded an existing theoretical model of Na + channel gating to include drug interactions (Online Data Supplement), which takes into account channel conformation dependence of drug accessibility and binding affinity and channel kinetics after drug binding. 22, 23 From experimentally obtained data, we first developed a model of ranolazine interaction with the wild-type cardiac Na + channel as described in the Online Data Supplement. 21 A depiction of the model is shown in Figure 1A . The model contains 8 discrete background states to represent the drugfree channel conformations (black) and 8 additional states (green) that represent drug-bound channel states. We also have included 4 additional states (not shown for clarity) to represent channel bursting 24 -a small population of channels that transiently fail to inactivate, producing a persistent Na + current that represents 0.1% of the peak Na + current as described for wild-type Na + channels. 25 The drug channel representation is based on assumptions derived from the modulated receptor hypothesis, which suggests that any discrete conformational state of the channel can exist in a drugfree or drug-bound form. 21, 22 Ranolazine binds to closed cardiac Na + channels (inhibitory concentration [IC 50 ]=165 μmol/L), indicated by resting tonic block at hyperpolarized membrane potentials that favor the closed channel conformation as in Figure 1B -dosedependent tonic block of peak current in solid line. Ranolazine also tonically blocks late Na + current with higher affinity (IC 50 =5 to 21 μmol/L). 10, 26 Simulated tonic block of late current is shown in Figure 1B (dashed line). The clinically relevant concentration range of drug is shown in yellow. Unlike some Na + channel-blocking drugs, 15, 27 ranolazine does not bind to inactivated Na + channels, because no shift in steady-state inactivation is observed on drug application ( Figure 1C ). In response to repetitive depolarization, ranolazine exhibits potent, open-state, use-dependent block (UDB; IC 50 =100.5 μmol/L), resulting from cumulative build-up of drug-bound channels and incomplete recovery during the interstimulus interval ( Figure 1D ). 28 UDB by ranolazine is frequency-dependent, with marked increases in UDB observed at faster pacing frequencies ( Figure 1E ). Ranolazine also dramatically slows Na + channel recovery from UDB after a rapid series of depolarizing pulses ( Figure 1F ). We then optimized a model of the LQT3-linked Na + channel mutation ΔKPQ to fit experimental data obtained from drugfree ΔKPQ mutant channels (Online Figure I) using the methods as described for wild-type and as described previously. 21 Notably, aside from a bursting-induced persistent Na + current of ≈0.5% of the peak Na + current, the ΔKPQ channel recovers slightly faster from inactivation but has similar mean open time, 29 peak current density, 30 steady-state availability, 31 and activation, 29 making ΔKPQ a particularly well-suited mutation to compare with wild-type for efficacy of mutation-specific persistent Na + current blockade.
Next, we modeled ranolazine effects on ΔKPQ mutant channels. Figure 2 shows the model fits (lines) to data Figure 1 . Schematic of the drug-channel interaction and simulated (lines) and experimental (symbols) ranolazine-wild-type Na + channel interactions. A, A schematic indicating drug-free and drug-bound model states. B, Dose dependence of tonic block for peak current (solid line) and late (dashed line) current. One depolarizing pulse from −100 to −10 mV was elicited. Block is peak current fraction normalized to drug-free conditions. C, Steady-state channel availability. Currents measured at −10 mV in drug-free conditions (dotted) or with 10 μmol/L ranolazine (solid) pulsed from −120 to −40 in 5-mV increments (normalized to tonic block at −120 mV). D, Dose dependence of use-dependent block (UDB) from 300 pulses to −10 mV for 25 ms from −100 mV at 5 Hz with indicated drug dose. Block is peak current at last pulse normalized to drug-free conditions. E, Frequency dependence of UDB. Protocol as in (D) at indicated pacing frequencies with 100 μmol/L ranolazine. F, Recovery from UDB induced by trains of pulses (−10 mV for 25 ms at 25 Hz) from −100 mV for drug-free (dashed) and with ranolazine (solid). Test pulses (−10 mV) were after variable recovery intervals at −100 mV. Currents were normalized to tonic block. B-F, The points are experiments and lines are simulations. Yellow boxes in (B) and (D) indicate therapeutic ranolazine. Figure 2 . Simulated (lines) and experimental (symbols) ranolazine-ΔKPQ mutant Na + channel interactions. A, Dose dependence of tonic block (TB) for peak current (solid) and late (dashed) current. One depolarizing pulse from −100 to −10 mV was elicited. Block is peak current normalized to drug-free conditions. Late current is measured after a 200-ms depolarizing pulse. B, Comparison of peak and late currents in wild-type and ΔKPQ mutant Na + channels. C, Steady-state channel availability. Currents measured at −10 mV in drug-free conditions (dotted) or with 10 μmol/L ranolazine (solid) pulsed from −120 to −40 mV in 5-mV increments (normalized to tonic block at −120 mV). D, Dose dependence of use-dependent block (UDB) from 300 pulses to −10 mV for 25 ms from −100 mV at 5 Hz with indicated drug dose. Block is peak current at last pulse normalized to drugfree conditions. E, Frequency dependence of UDB. Protocol is as in (D) at indicated pacing frequencies with 10 μmol/L ranolazine. F, Recovery from UDB induced by 100 pulses (−10 mV for 25 ms at 25 Hz) from a −100 mV in drug-free conditions (dotted), 10 μmol/L ranolazine (solid top), and 100 μmol/L ranolazine (solid bottom). Test pulses (−10 mV) were after variable recovery intervals at −100 mV. Currents were normalized to tonic block. Yellow boxes in (A) and (D) indicate therapeutic ranolazine.
(symbols) following parameter optimization for ranolazine interaction with ΔKPQ channels. The clinical range of the drug is shown in yellow. Figure 2A shows the differential sensitivity of ranolazine to peak (IC 50 =120.8 μmol/L) and late (IC 50 =12.7 μmol/L) ΔKPQ current elicited by a single depolarizing pulse. The data summary ( Figure 2B ) reveals that peak current from ΔKPQ channels is slightly more sensitive to blockade by ranolazine than wild-type (IC 50 =120.8 vs 165.2 μmol/L). Ranolazine blocks late vs peak Na + current preferentially by a factor of 9.5, consistent with previously published reports. 32, 33 Importantly, experiments indicate that even though ranolazine preferentially blocks late current, ΔKPQ is 2-fold less sensitive to blockade of the late component of the Na + current when compared with wild-type (12 vs 6 μmol/L, respectively). Ranolazine minimally shifted the ΔKPQ steady-state inactivation curve (<2 mV), indicating low inactivated state affinity ( Figure 2C ). At 5 Hz pacing, ΔKPQ channels exhibit a similar extent of UDB by ranolazine as wild-type channels (IC 50 for peak Na + current blockade: 83 and 100.5 μmol/L, respectively; Figure 2D ). However, the rate dependence of UDB for ΔKPQ channels was markedly blunted compared with wild-type channels (compare panel E in Figure 1 ). Figure 2F shows that ΔKPQ channels also recover from UDB induced by 10 μmol/L ranolazine faster than wild-type channels.
Ranolazine Binds to the Promiscuous Drug Target hERG
Ranolazine is a potentially promising therapeutic for LQT3 patients because of its targeting of I NaL but is contraindicated for LQTS patients because of off-target interactions with the promiscuous drug target hERG, which underlies the key human repolarizing current I Kr . The rapid kinetic interaction of ranolazine with hERG yields frequency-independent block, thus allowing for a much simplified model representation compared with that required for the Na + channel. 34 Thus, to account for the off-target interactions of ranolazine with hERG, we incorporated a concentration-dependent block of I Kr peak using a concentration-response relationship with a Hill coefficient of 1 (n=1). Multiple studies concur that ranolazine blocks hERG with an IC 50 of I Kr =12 μmol/L. 10, 34 Clinical studies also suggest hERG blockade; administration of 2 to 6 μmol/L ranolazine yields a proportional increase in QTc of 2 to 6 ms. 26, 35 We performed simulations in a 1-dimensional (1D) transmural tissue informed by human data (Online Data Supplement) comprising 165 cardiac cells and simulated the effect of 6 μmol/L ranolazine on the computed electrogram generated by the model. In the model, we observed a marked QTc prolongation of 40 ms, a prediction that was not consistent with the clinical data.
A survey of the literature revealed a plausible and testable explanation for the discrepant model predictions and clinical findings. Pharmacokinetic studies of ranolazine suggest extensive metabolism via cytochrome P450, family 3, subtype A-mediated pathways of biotransformation, with <5% of the parent compound unmetabolized. 20 Four predominant metabolites were identified in healthy volunteers at plasma concentrations 30% to 40% of the parent compound, all of which produce a substantially weaker inhibition of I Kr (40%-50% inhibition at 50 μmol/L). IC 50 values for an additional 7 metabolites tested were all >50 μmol/L. 26 Importantly, in contrast, all 11 metabolites potently inhibited I NaL by 12% to 57% at 10 μmol/L. 26 In light of this pharmacokinetic data, we used the model to make a prediction about the role of weaker ranolazine metabolite inhibition of I Kr to explain the clinically observed changes in QTc on ranolazine administration. Shown in Figure 3A (Online Figure II) are computed electrograms from transmural tissues spanning the range of measured affinities (50-12 μmol/L) for the parent compound ranolazine and its metabolites on I Kr . Notably, an intermediate value that best reflects the physiological situation encompassing a weighted average of I Kr inhibition from high-affinity block by ranolazine and low-affinity block by metabolites produced 8 ms prolongation of computed QTc at 6 μmol/L ranolazine, fully consistent with clinical data. 26 In Figure 3B , the predicted concentration-dependent increase in QTc with increasing doses of ranolazine is shown. Low-dose ranolazine (2 μmol/L) increased QTc by 2.5 ms, whereas highdose ranolazine (10 μmol/L) increased the QTc by 14 ms. The simulated QTc-prolonging effects are approximately linear, with a slope of ≈3 ms per 1000 ng/mL, consistent with the clinically observed change of 2.4 ms per 1000 ng/mL. 26 
Potential for Ranolazine to Normalize ΔKPQ Arrhythmia Triggers
To explore the potential for ranolazine to improve abnormal cellular electric phenotypes arising from the ΔKPQ mutation, we incorporated the channel model with and without drug in the O'Hara et al 36 (Figure 4 , left) and Grandi et al 37 (Figure 4 , right) human ventricular myocyte models. The ten Tusscher et al 38, 39 model is shown in Online Figure III . We conducted simulations in the full complement of existing human ventricular AP models to ensure model independence of our predictions. Consistent with experimental data 30, 32, 40 and previous computationally based studies, the ΔKPQ mutation led to dramatic AP duration (APD) prolongation that worsened with slowing of pacing frequency. As shown in Figure 4 for each model, after 500 stimuli at bradycardic pacing intervals, the ΔKPQ mutation resulted in persistent late Na + current ( Figure 4B ) and continued arrhythmogenic early afterdepolarizations (EADs) that arose from an extended phase 2 plateau ( Figure 4A ), which allowed for reactivation of the L-type Ca 2+ channel ( Figure 4C ). For Figure 4B and 4C, peak currents of both Na + and L-type Ca 2+ currents are off-scale. Within the therapeutically relevant range, both high-dose (10 μmol/L, teal lines) and low-dose (5 μmol/L, red lines) ranolazine normalized the ΔKPQ AP morphology, an effect that was model-independent. Figure 4D shows a summary of the effects of clinically relevant concentrations of ranolazine on ΔKPQ APD and cellular excitability (upstroke velocity of the AP) for simulated epicardial cells at nominal pacing (basic cycle length, 1000). Over the clinically relevant dosing regimen (1-10 μmol/L), ranolazine effectively normalizes APD without compromising cellular excitability, a potentially confounding occurrence and cellular-level marker that was previously shown to be strongly proarrhythmic in coupled tissue. 21 Because there was minimal upstroke velocity depression, we further tested supratherapeutic ranolazine (15 and 20 μmol/L) and found similar results.
Efficacy of Ranolazine to Normalize Pause-Induced EADs
It has been widely documented that LQT3-linked arrhythmias are typically preceded by sinus pauses and short-long-short sequences. [41] [42] [43] [44] [45] The presumed mechanisms have been shown experimentally and predicted computationally and result from the emergence of EADs on APs triggered after a pause. Thus, ideal drug therapy for LQT3 patients must normalize arrhythmia triggers occurring subsequent to long diastolic intervals. A, Cellular APs. B, Na + currents (peak off-scale). C, L-type Ca2+ currents (peak off-scale). In both models, low (5 μmol/L) and high (10 μmol/L) ranolazine progressively shorten the action potential duration (APD) but fail to fully normalize to wild-type (blue line). D, Concentration-dependent effects of ranolazine on APD and upstroke velocity (UV) at BCL 1000. Note that although APD is normalized, UV remains robust with high therapeutic concentrations of drug.
We used computational 1D transmural tissue models to test the potential for ranolazine to normalize APs after long rest intervals in coupled tissue.
Shown in Figure 5A is a space-time-membrane voltage plot showing the last 3 S1 beats (stars) at basic cycle length 750 (after steady-state pacing, 500 beats), followed by an S2 (arrow) stimulus applied after a 1.05-second pause. Underneath each voltage in the time plot is a computed electrogram from the tissue. The electrogram in Figure 5A shows an early downward deflection attributable to EAD generation that occurs first in endocardial cells. Flattening of the electrogram then occurs and finally a positive t-wave deflection as epicardial cells repolarize before endocardial cells. Figure 5B and 5C shows the effect of pretreatment with moderate (5 μmol/L) and high (10 μmol/L) clinical doses of ranolazine. The model predicts that 5 μmol/L ranolazine improves the cellular phenotype after the pause but is unable to fully normalize the arrhythmogenic trigger after the pause ( Figure 5B ). High-dose ranolazine application ( Figure 5C ), however, completely prevents EAD formation after a long pause.
We next quantified the effect of high and low concentrations of ranolazine to prevent pause-induced arrhythmia triggers over a physiologically relevant pause interval range. Shown in Figure 5D is the increase in pause length threshold for EAD normalization after pretreatment with drug at 5 and 10 μmol/L ranolazine after pacing to steady state at basic cycle length of 750. The simulations suggest that high-dose ranolazine can normalize EADs when the incident pause is <1150 ms. Supratherapeutic levels of ranolazine, which in Figure 4 is shown to maintain upstroke velocity in single cells, substantially increases the pause duration safety window before arrhythmogenic EADs are noticed (2150 ms at 20 μmol/L).
Thus far, our model simulations have suggested that within the clinically relevant dosages, ranolazine resolves arrhythmia triggers that result from persistent LQT3-linked Na + current. We next wanted to test whether ranolazine had the potential to normalize arrhythmia triggers stemming from acquired dysfunction such as human heart failure, which has been linked to a pathological increase in I NaL and suggested as a potential therapeutic target. 46, 47 
Formulation of a Human Heart Failure Model
The range of heart failure phenotypes is complex, and there currently exists no adequate computational model that incorporates the myriad ionic and hormonal dysregulation found in endstage ischemic heart disease. We thus turned to the literature [48] [49] [50] to find the most up-to-date and reproducible human heart failure data and incorporated the deranged ionic fluxes into the Grandi et al 37 human ventricular model. We chose the model of Grandi et al because it incorporates intricacies of Ca 2+ handling that are known to play a key role in Ca 2+ -induced arrhythmia triggers. We combined the Grandi et al model of the AP with the Soltis and Saucerman 51 model formulation of the β-adrenergic pathway. This includes Ca 2+ /calmodulin-dependent protein kinase II and protein kinase A signaling, important regulatory pathways shown to be upregulated in human heart failure. 52 Complete details of our human heart failure model formulation can be found in Online Table VI .
In Figure 6 , we show cellular simulations generated by the human heart failure model. Figure 6A shows a prolonged APD under the influence of 1 μmol/L isoproterenol, consistent with experiments. 49, 53 Other important ionic fluxes include an outward shift in Na + /Ca 2+ exchange (NCX) current ( Figure 6C ), reduced intracellular Ca 2+ transient ( Figure 6D ), a delayed recovery of sarcoplasmic reticulum Ca 2+ load ( Figure 6E) , an increased I NaL optimized to yield ≈1% late current ( Figure 6F ), 54 and an increased intracellular Na + concentration ( Figure 6G) 48, 50 also attributable to increased I Na,L and Na + leak current (I Na,leak ), and decreased Na + /K + -ATPase (NKA). Summary data comparing experiment to simulation are shown in Figure 6H . A, Space-time plot of 3 S1 beats at basic cycle length (BCL) 750 (*after steady state pacing, 500 beats) in the absence of drug. A 1050-ms pause, followed by an S2 stimulus (arrows), elicits an EAD throughout the 165-cell cardiac 1-dimensional tissue. B, Pretreatment with 5 μmol/L ranolazine is insufficient to abolish the EAD throughout the tissue, but with pretreatment of 10 μmol/L ranolazine (C) the S2 stimulus fails to elicit an EAD and monotonic repolarization is restored. A-C, The x axis is time, y axis is cell number, and z axis is voltage. A computed ECG is underneath the space-time plot. D, The pause necessary to elicit an EAD increases with drug concentration after steady-state pacing (500 beats) at BCL 750. The O'Hara et al 36 model was used for this simulation. September 13, 2013
Efficacy of Ranolazine to Ameliorate Heart Failure-Induced Arrhythmia Triggers
A hallmark arrhythmia trigger in human heart failure is the occurrence of Ca 2+ -induced delayed afterdepolarizations (DADs). Although the complete pathway is not fully elucidated, Ca 2+ modulation of the Na + channel has been demonstrated 55, 56 via Ca 2+ /calmodulin-dependent protein kinase II, 57 and multiple upstream pathways converge on pathological I NaL (eg, increased mitochondrial oxidative phosphorylation, 58 increased ROS, 58, 59 increased Na + /H + exchange, 60-62 decreased NKA). 63 Increased I NaL and increased intracellular Na + then lead to increased [Ca] i via NCX and ultimately mechanical and electric instabilities (eg, DADs, beat-to-beat variability in APD), leading to further ischemia and ventricular arrhythmias. 18 In Figure 7 (and expanded analysis in Online Figures V-VII), we tested the effects of ranolazine to inhibit DAD generation under conditions of heart failure in the presence of β-adrenergic stimulation. After conditions of tachycardic pacing (basic cycle length, 500), Figure 7B Figure 7C depicts a more severe derangement (20% decrease in NKA; 6-fold increase in I Na,leak ), eliciting 4 spontaneous beats (red arrowheads, Figure 7C, left) , which is again ameliorated by 5 μmol/L ranolazine ( Figure 7C, right) . An expanded analysis of ionic current changes for this severe condition ( Figure 7C ) is in Online Figure XI . Of note, no data exist for the affinity of ranolazine to I Na,leak ; for these simulations, we assumed that I Na,leak had similar affinity to wild-type I NaL (6 μmol/L). For completeness, we also tested differing ranolazine affinities to I Na,leak in Online Figures IX and X. Figure 7D summarizes the results of simulations spanning physiologically reasonable range of combinations of increased Na + leak and decreased NKA. When Na + leak is increased 10-fold, full repolarization failure occurs over all conditions tested (blue circles in top row of Figure 7D, left) . Figure 7D , right, shows ranolazine is (I NCX ) . D, intracellular Ca 2+ transient. E, sarcoplasmic reticulum Ca 2+ load. F peak I Na current (note peak off-scale). G, intracellular Na + concentration. H, Comparison between experiments and simulations for action potential duration 36, 37, 49, 53, 75 and [Na] i . 48, 50 Both experiments and simulations were at 1 Hz (BCL 1000 ms). effective at restoring repolarization and inhibiting DAD generation in the majority of physiologically plausible conditions tested (compare blue circles and red arrowheads, left, to filled circles, right).
Finally, in Figure 8 and Online Figure XIII , we probed the model components to reveal the ionic mechanism for ranolazine efficacy for one of the conditions tested in Figure 7 , namely an 8-fold increase in Na + leak and 10% decrease in NKA (condition in Figure 7B ). As compared with control ( Figure 8, column 1) , the heart failure condition exhibits an ≈20% increase in [Na + ] i (Figure 8B , column 2 vs column 1), which slows inward NCX (Ca 2+ extrusion) and enhances outward NCX (Ca 2+ entry, at the beginning of the AP). This coupled with AP prolongation due to extensive ionic remodeling in HF allows increased Ca 2+ entry and maintains adequate sarcoplasmic reticulum Ca 2+ load and Ca 2+ transient despite reduced sarco/endoplasmic reticulum Ca2+-ATPase function. However, [Na + ] i -induced Ca 2+ enhancement in combination with hypersensitive ryanodine receptors causes diastolic sarcoplasmic reticulum Ca 2+ release and the occurrence of a spontaneous Ca 2+ transient ( Figure 8C , column 2 vs column 1, red arrowhead). This Ca 2+ is extruded by NCX, which generates an inward current ( Figure 8D , column 2, red arrowhead) that depolarizes the membrane potential leading to I Na activation and triggers AP ( Figure 8A , column 2 vs column 1, red arrowhead). Note that the more depolarized resting membrane potential in HF (due to decreased I K1 and increased I Na,leak ) is likely to favor AP triggering. Application of 5 μmol/L ranolazine partly normalizes [Na + ] i ( Figure 8B , column 3 vs column 1) and inward NCX ( Figure 8D, column 3) and abolishes the spontaneous Ca 2+ transient ( Figure 8C , column 3) and triggered AP ( Figure 8A, column 3) . Notably, ranolazine also hyperpolarizes the resting membrane potential, thus elevating the threshold for triggered diastolic events. These simulations are fully consistent with recent experimental data for a hypertrophic cardiomyopathy experimental model with ranolazine 64 and suggest that even moderate dose of ranolazine may be an appropriate antiarrhythmic therapeutic for the prevention of arrhythmia triggers driven by spontaneous sarcoplasmic reticulum Ca 2+ release.
Discussion
Recently, there has been interest in the antiarrhythmic potential of the novel antianginal agent, ranolazine, the first Food and Drug Administration-approved drug that specifically blocks the late component of the Na + current. Like most antiarrhythmics that target cardiac ion channels (eg, flecainide and amiodarone), ranolazine blocks multiple channels, including the repolarizing hERG current I Kr , with therapeutic concentrations. The result is a mild concentration-dependent QTc prolongation seen in patients with chronic stable angina. 11 Because of this, ranolazine is contraindicated for patients using other QT-prolonging drugs, those with preexisting QT prolongation, 12 and those with repolarization abnormalities.
In this study, we sought to use a computationally based approach to determine whether ranolazine's unintended Figure 7 . Effects of ranolazine on delayed afterdepolarization (DAD) generation under heart failure (HF) conditions. A, control. B, HF condition of 10% decrease in Na + /K + ATPase (NKA), 8-fold increase in Na + leak. C, HF condition of 20% decrease in NKA, 6-fold increase in Na + leak. A-C, Column 1 is drug-free, and column 2 is with 5 μmol/L ranolazine. Red arrowheads over action potentials indicate nonpaced beats (DADs) that were observed after stimulus was removed. D, Summary data for parameter space spanning plausible ranges of decreased NKA and increased Na + leak. • , Absence of DADs; upside-down red triangles, presence of DADs; blue circles, repolarization failure.
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September 13, 2013 pathological block of promiscuous K + channels would prevail over therapeutic drug effects in 2 specific patient populations: LQT3-ΔKPQ carriers and those with acquired arrhythmias arising from heart failure. With regard to congenital LQT3, although many in vitro studies [65] [66] [67] [68] have suggested ranolazine as an ideal therapeutic, to date, only 1 clinical study has been performed on a small number (5 carriers) of ΔKPQ mutation-afflicted patients. 69 Moss et al 69 showed an unequivocal decrease in QTc with ranolazine treatment in these patients (4% decrease in QTc at ≈5 μmol/L), but because of its small size and limited end points, it is unclear if ranolazine would be effective at preventing bradyarrhythmias rather than just impacting surrogate markers of arrhythmia (eg, the corrected QT interval).
When we tested ranolazine in cellular simulations, we found another potential mechanism of safety that, unlike other Na + channel blockers (eg, flecainide and lidocaine), ranolazine does not cause a decrease in cellular excitability and tissue conduction velocity. 21 Another drug that had similar promise was the lidocaine oral analog mexiletine. Although mexiletine was proven useful in a small clinical trial of LQT3 patients, 70 it has proarrhythmic side effects like many other antiarrhythmic drugs. Sustained ventricular tachycardia has been reported, 71, 72 as well as exacerbation of arrhythmia in 10% to 15% of patients. 73 More importantly for the LQT3 patient population, in which the characteristic phenotype is a bradyarrhythmia, mexiletine is associated with sinus node depression, resulting in sinus bradycardia and prolonged sinus node recovery time, 71, 73 potentially exacerbating the arrhythmia phenotype.
Clinical studies have shown that administration of ranolazine in the clinic (2-6 μmol/L) causes proportional increases in QTc of 2 to 6 ms, 26, 35 presumably arising from hERG block. Therefore, we would have expected to see ≈6 ms increase in the QTc on our computed electrograms when model tissues were pretreated with 6 μmol/L ranolazine with incorporation of the rapid blockade of hERG. 34 Instead, we observed a dramatic QTc prolongation (40 ms), a prediction that was not consistent with the clinical data ( Figure 3A) .
However, when we additionally considered the effects of active metabolites of ranolazine, the simulation confirmed clinical findings. Like most drugs, ranolazine undergoes extensive metabolism, primarily via the cytochrome P450, family 3, subtype A system, with <5% of the parent compound excreted in the urine unchanged. 20 All 11 active metabolites potently inhibit I NaL by 12% to 57% at 10 μmol/L, similar to the parent compound. 26 In contrast, the 4 predominant metabolites comprising 30% to 40% of the parent compound produce substantially weaker inhibition of I Kr (40%-50% inhibition at 50 μmol/L). IC 50 values for an additional 7 metabolites tested were all >50 μmol/L. 26 Our model simulations suggested that a weighted average of the affinities of parent compound and active metabolites led to an apparent affinity for ranolazine and metabolites for I Kr in the range of 35 μmol/L, causing the clinically observed moderate changes in QTc. Thus, there exists a large margin of safety for drug administration of ranolazine that reflects the difference in ranolazine affinity, and targeting, for I Kr and I NaL .
We validated our model predictions against surrogate markers of arrhythmia risk (eg, normalization of the QT interval) and then sought to determine if ranolazine could prevent pause-induced EADs, a clinically significant precedent event to torsades de pointes. 45, 74 We found that a pacing interval of 750 ms, a minimal pause (≈100 ms) that extended the diastolic interval beyond normal (S2=850 ms), induced AP prolongation and EAD triggers in a transmural tissue model. Pretreatment of the cardiac fiber with high therapeutic ranolazine (10 μmol/L) delayed the onset of EAD generation by 35% (S2=1150 ms compared with 850 ms in drug-free conditions).
In a comprehensive review of the incidence of pausedependent torsadogenic arrhythmias in congenital LQTS, Viskin et al 45 found an average precedent pause was ≈1000±300 ms, similar to the threshold range we predicted with ranolazine treatment. We then tested supratherapeutic ranolazine (15-20 μmol/L) because of the promising results of robust upstroke velocity in single cells, and we found a dramatic increase in the safety window of a pause necessary to elicit an EAD (2150 ms). This suggests that high-dose ranolazine may reduce the need for cardiac pacing, which itself perpetuates the short-long sequence of torsades de pointes, 45 but clinical studies of ranolazine with Holter ECG recording will be needed to confirm this clinically relevant prediction.
By targeting pathological late Na + current, ranolazine shows therapeutic promise for treatment of I NaL -induced arrhythmias, both congential and acquired. Mechanistically, ranolazine does this by limiting [Na + ] i and restoring normal NCX forward mode that limits Ca 2+ entry via NCX and speeds up Ca 2+ extrusion, by shortening APD, thus further limiting Ca 2+ entry, and by hyperpolarizing the membrane potential, which elevates the threshold of triggered activity (presumably by ranolazine's effect on I Na,leak , a hypothesis borne out by recent experiments 64 and suggested by the model). We simulated a physiologically realistic transmural ventricular cardiac tissue based on data obtained from transmural wedge preparations from both normal and failing human myocardium. 49 The simulations recapitulated a modest decrease in QTc with therapeutic ranolazine (5 μmol/L) and showed that higher dose of ranolazine (10 μmol/L) can decrease the QTc interval at static pacing (≈12% decrease in QTc).
For LQT-ΔKPQ carriers, ranolazine can also ameliorate the effects of pause-induced EADs, a hallmark clinical precedent to torsades de pointes. In the heart failure setting, we found that even moderate dose of ranolazine (5 μmol/L) was predicted to nearly normalize many of the derangements in intracellular ionic concentrations and aberrant currents, which led to an effective abolishment of arrhythmia triggers. Of note, this therapeutic effect may be specific to LQT arising from elevated I NaL . In the absence of substantial I NaL , the model predicts that ranolazine will prolong APD and consequently QT interval (Online Figure XII) .
Because there exists heterogeneity of heart failure phenotype severity, we attempted to survey a wide parameter space, including the effects of varying I Na,leak and NKA expression. We found that phenotypes arising from a large component of I Na,leak are more susceptible to ranolazine blockade than those from decreased NKA expression. We also found that even a moderate dose of ranolazine (5 μmol/L) shows efficacy in suppressing spontaneous depolarizations (Figure 7, right) , and high-dose ranolazine (10 μmol/L) suppresses all but the 2 most severe phenotypes (Online Figure VII) .
In summary, we have built genotype-specific computational models of the LQT3-ΔKPQ mutation and a human heart failure model to specifically test a therapeutic intervention that targets the aberrant molecular mechanism (persistent late Na + current) in 2 different pathological settings. Our multidimensional framework largely relies on experimental functional data but is refined and validated by clinical electrophysiological data from numerous clinical trials. The results of our study suggest that the therapeutic potential of ranolazine derives largely from metabolism of the parent compound into active metabolites that show significant selectivity between repolarizing current blockade (I Kr ) and pathological current blockade (I NaL ). Computational modeling of the effects of metabolism is, thus, vitally important for accurate and physiologically realistic electrophysiological models of drug blockade. Our studies extend the results of the clinical literature to show that ranolazine further ameliorates the effects of specific torsadogenic activation sequences common to LQT carriers as well as selectively targeting upstream pathways, which lead to mechanical and electric instability within the ischemic heart failure setting. Both results suggest potential avenues for further clinical testing.
This study represents one step toward construction of an in silico, high-throughput drug testing system based on specific genetic defects as well as a continuum of acquired syndromes. Computational models of the kind we present in this study can be used to test vast parameter spaces that include variation in severity of disease. This may allow for rapid preclinical identification of potentially proarrhythmic or antiarrhythmic agents with high fidelity, unencumbered by problems inherent to large-scale clinical trials, which are heterogeneous in patient population and disease severity. Our approach constitutes a tractable methodology to determine which agents merit further testing with experiments and tailored clinical trials.
Disclosures
What Is Known?
• Drug therapy for long-term management of cardiac arrhythmia has had limited success, in part, because it is difficult to predict how drug therapy will alter the emergent electric behavior of the heart. • Ranolazine is contraindicated for patients using drugs that prolong the QT interval or those with preexisting QT prolongation because its off-target effects could worsen these conditions. • Patients with QT prolongation attributable to inherited defects or disease might benefit from drugs like ranolazine that target the pathological late Na current.
What New Information Does This Article Contribute?
• We developed a computational framework to predict the effects of ranolazine in 2 distinct disease states marked by late Na current, inherited long-QT syndrome type 3, and heart failure.
• The computational modeling framework is used to improve understanding of antiarrhythmic drug actions across multiple spatial scales of the cardiac system, from molecule to channel, to cell, and to tissue. • Our simulated data suggest that ranolazine may be effective in preventing multiple types of arrhythmia triggers that arise from late I Na .
In this study, we adopted an interdisciplinary approach combining laboratory experiments, computational biology, high-performance computing, and clinical observation. Collectively, this led to the development of a computational approach to predict the effects of a drug in specific disease states that promote cardiac arrhythmia. We used this approach to predict if ranolazine would be useful in 2 distinct clinical syndromes associated with an increase in pathological Na. This framework forms a base that can be readily expanded for virtual drug screening of other agents.
Novelty and Significance
